NCT01457950View on ClinicalTrials.gov

A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

PHASE3CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

June 30, 2013

Conditions
Osteoporosis, Postmenopausal
Interventions
DRUG

denosumab

double-blind phase: 60mg subcutaneous injection, single dose

DRUG

placebo

double-blind phase: placebo subcutaneous injection, single dose

DRUG

open-label denosumab

open-label phase: 60mg subcutaneous injection, single dose

Trial Locations (10)

602-739

GSK Investigational Site, Busan

Unknown

GSK Investigational Site, Daegu

501-757

GSK Investigational Site, Gwangju

100-380

GSK Investigational Site, Seoul

110-744

GSK Investigational Site, Seoul

120-752

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Songpa-gu, Seoul

443-721

GSK Investigational Site, Suwon

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01457950 - A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab | Biotech Hunter | Biotech Hunter